The randomized, double-blind, sham-controlled trial evaluated 56 adults with ADHD who received four weeks of Nexalin’s ...

A 150-child trial found an FDA-cleared ADHD stimulation device did not significantly reduce symptoms, raising concerns over ...

Add Yahoo as a preferred source to see more of our stories on Google. At-home neurostimulation devices claim to lessen the symptoms of anxiety and chronic pain (Pulsetto) For most, the idea that you ...

For many people living with multiple sclerosis (MS), walking can become one of the most challenging daily tasks. As many as 3 in 4 people with MS have gait issues caused by factors like loss of muscle ...

On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an ...

HOUSTON, TEXAS, March 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation ...

HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced ...

NEW YORK, July 31, 2024 /PRNewswire/ -- The global neurostimulation devices market size is estimated to grow by USD 6.26 billion from 2023-2027, according to Technavio. The market is estimated to grow ...

Credit: Neurovalens. Modius Sleep is an electrical vestibular nerve stimulator that sends signals to a neural pathway that connects to the hypothalamus. Modius Sleep lowered Insomnia Severity Index by ...

Inspire Medical Systems’ growth strategy is focused on ensuring strong clinical outcomes, driving manufacturing capabilities, ...

Shares of Nexalin Technology nearly doubled after the company said its second-generation Sync neurostimulation device can improve cognitive performance and enhance brain network connectivity in ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...